Dr. Reddy's shares in focus as EC clears biosimilar used to treat Osteoporosis

Shares of Dr. Reddy's Laboratories will be in focus on Tuesday, November 25, after the company announced that the European Commission (EC) has granted marketing authorisation for AVT03, a biosimilar of Prolia® (denosumab) and Xgeva® (denosumab).

Prolia® is prescribed for treating osteoporosis in postmenopausal women, men at high fracture risk, bone loss caused by hormone ablation in men with prostate cancer, and bone loss resulting from long term systemic glucocorticoid therapy.

Xgeva® is used to prevent bone related complications in adults with advanced cancers that have spread to the bone, and for treating adults and skeletally mature adolescents with giant cell tumour of bone.

The EC approval comes after the Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion in September 2025.

The authorisation applies across all EU Member States as well as EEA countries including Iceland, Liechtenstein, and Norway.

Shares of Dr. Reddy's Laboratories closed 1.60% lower on Monday at ₹1,224. The stock is down 11% so far this year.